Cited by 557Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 489 of the 506 references it cites were found in a registry or an index.

RAF-MEK-ERK pathway in cancer evolution and treatment

Ullah, Rahim, Yin, Qing, Snell, Aidan H., Wan, Lixin·2022·Seminars in Cancer Biology

DOI 10.1016/j.semcancer.2021.05.010

Open this paper in CoChat — free account

Abstract

The RAF-MEK-ERK signaling cascade is a well-characterized MAPK pathway involved in cell proliferation and survival. The three-layered MAPK signaling cascade is initiated upon RTK and RAS activation. Three RAF isoforms ARAF, BRAF and CRAF, and their downstream MEK1/2 and ERK1/2 kinases constitute a coherently orchestrated signaling module that directs a range of physiological functions. Genetic alterations in this pathway are among the most prevalent in human cancers, which consist of numerous hot-spot mutations such as BRAF V600E. Oncogenic mutations in this pathway often override otherwise tightly regulated checkpoints to open the door for uncontrolled cell growth and neoplasia. The crosstalk between the RAF-MEK-ERK axis and other signaling pathways further extends the proliferative potential of this pathway in human cancers. In this review, we summarize the molecular architecture and physiological functions of the RAF-MEK-ERK pathway with emphasis on its dysregulations in human cancers, as well as the efforts made to target the RAF-MEK-ERK module using small molecule inhibitors.

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2021.05.010

Cites

489 of 489 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
On the origin of cancer cells
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
AMPK: guardian of metabolism and mitochondrial homeostasis
Herzig, S., & Shaw, R. J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.95 · Cited by 4,192
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G. W., Robinson, F. L., Gibson, T. B., Xu, B.-E., Karandikar, M. S., Berman, K. S., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,111
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,060

Flagged first, then by citations

Show all 506 references

17 of the 506 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Pagès, 1999, Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice, Science, 286, 1374, 10.1126/science.286.5443.1374 · DOI · Paper page

Sorted by citations

Items 301–400 of 557

PHLPP: a Janus-faced regulator in oncogenesis
Huang, J., Zhao, Y., Guan, J., Zhang, X., & Wu, D. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153104 · Cited by 2
Comprehensive pan-cancer analysis of TRAP1 and its experimental validation in hepatocellular carcinoma
Shan, S., Wang, T., Sun, F., Zhao, L., Liang, S., & Wang, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-04238-9 · Cited by 2
“The RTK-RAS-MAPK signaling pathway is also critical for cell proliferation, and its dysregulation often leads to tumor development and progression [40, 41].”
Phlorotannins from Ecklonia cava Regulate Dual Signaling Pathways, IL-17RA/Act1 and ERK1/2, to Suppress Ovarian Cancer Progression and Tumor-Associated Macrophage Activation
Kim, E.-H., Lee, H.-H., Choi, J. Y., & Ahn, J.-H. (2025) · Marine Drugs · doi:10.3390/md24010012 · Cited by 3
“The ERK1/2 cascade represents a crucial pathway not only in cell proliferation and survival but also in maintaining epithelial integrity and controlling metastasis-related gene expression [27].”
Targeting the MAPK Pathway in Brain Tumors: Mechanisms and Therapeutic Opportunities
Vrachas, D., Kosma, E., Giannopoulou, A.-I., Margoni, A., Gargalionis, A. N., El-Habr, E. A., Piperi, C., & Adamopoulos, C. (2026) · Cancers · doi:10.3390/cancers18010156 · Cited by 2
“Among them, the rapidly accelerated fibrosarcoma (RAF), the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK), and the extracellular signal-regulated kinase (ERK) form the RAF-MEK-ERK signaling axis, the central and most thoroughly studied MAPK pathway [8,9] (Figure 1).”
Mechanistic study of glutamine metabolic reprogramming driving non-small cell lung cancer progression via the FGF17-FGFR4 axis mediating epithelial-mesenchymal transition
Kong, Q., Wang, X., & Ding, W. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1728698 · Cited by 2
Whole-Body Knockout of the AhR (Aryl Hydrocarbon Receptor) Ameliorates Atherosclerosis Due to Altered Lipid Metabolism—Brief Report
Huchzermeier, R., de Jong, R. J., Rakateli, L., Bonnin-Marquez, A., Maas, S. L., Pöttgens, C. C. H., Abschlag, K., Jin, H., Geiselhöringer, A.-L., Triantafyllidou, V., et al. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.323673 · Cited by 2
“20 Besides its effect on inflammatory pathways, Ahr deficiency also affected liver kinases involved in lipid metabolism, which aligns with our previous observations, as well as kinases involved in glucose metabolism (Table S1).”
Precision Exercise in Type 2 Diabetes Mellitus: Targeting Signaling Networks for Lipid Homeostasis
Tian, T., Yu, F., Liu, X., Zeng, X., Yue, J., & Bao, S. (2026) · Metabolites · doi:10.3390/metabo16040269 · Cited by 2
“Dysregulation of this pathway has been implicated in rheumatoid arthritis, cancer, and T2DM [79,80].”
MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC
Li, C., Deng, S., Zhuang, M., Li, T., Lin, L., Zheng, L., Lin, K., Li, D., & Chen, F. (2026) · Oncogene · doi:10.1038/s41388-026-03795-9 · Cited by 2
“It is generally considered that widespread ampli ﬁ cation and oncogenic mutations of EGFR, KRAS, and BRAF contribute to dysregulation of the MAPK pathway in CRC, thereby promoting tumor initiation, maintenance, and metastasis [3].”
Copper homeostasis and cuproptosis in cancer: mitochondrial metabolic dependency and nanomedicine-based therapeutic strategies
Han, X., Peng, Z., Cao, K., & Liang, G. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02352-9 · Cited by 3
Insight into the relationships of structure and anti-tumor effects of Glucuronomannan oligosaccharides (Gx) and its derivatives on the A549 lung adenocarcinoma cells
He, X., Wang, S., Cai, M., Qiao, P., Mao, G., Jin, W., & Zhong, W. (2023) · Algal Research · doi:10.1016/j.algal.2023.102979 · Cited by 2
[Colorectal cancer cells induce the formation of cancer-associated fibroblasts by activating the ERK signaling pathway in fibroblasts].
Deng, T., DU, B., & Xi, X. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.06.09 · Cited by 3
Molecular network mechanism of Shexiang Huayu Xingnao granules in treating intracerebral hemorrhage
Liu, K., Bai, X. H., Chen, J., Chen, G., Jamal, M. A., & He, Y. (2023) · Ibrain · doi:10.1002/ibra.12131 · Cited by 2
“22 The STAT3 gene is a key transcription factor in the JAK2/STAT3 signaling pathway, and activated JAK2 protein can induce tyrosine residues of downstream target proteins to enrich and phosphorylate STAT3 so that it enters the nucleus and binds to the target gene, thereby regulating cellular…”
Background
Inhibition of USP21 leads to ovarian carcinoma cell death by suppressing MAPK signaling
Sun, X., Yu, J., Cui, X., Tang, Y., & Yu, Y. (2023) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2535 · Cited by 2
SAA1 regulated by S1P/S1PR1 promotes the progression of ESCC via β-catenin activation
Li, Q., Tang, M., Zhao, S., Yang, J., Meng, Y., Meng, C., Ren, L., & Hu, W. (2024) · Discover Oncology · doi:10.1007/s12672-024-00923-3 · Cited by 2
“3, and ERK phosphorylation is closely related to tumor cell proliferation and migration [28, 29].”
Background
[Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].
Deng, L., Yang, Y., & Huang, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.101.01 · Cited by 2
Isovaleryl Sucrose Esters from Atractylodes japonica and Their Cytotoxic Activity
Wang, Y., Wang, Z., Sun, Y., Zhu, M., Jiang, Y., Bai, H., Yang, B., & Kuang, H. (2024) · Molecules · doi:10.3390/molecules29133069 · Cited by 2
“The BRAF and FGFR genes are aberrantly expressed in a variety of cancers, as evidenced by studies [17,18].”
Background
Mechanism of Guishao Yigong decoction in treating colorectal cancer based on network pharmacology and experimental validation
Fan, Y., Wang, Q., Zhang, Y., Wang, Y., Li, W., Jiang, S., & Duan, J. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae045 · Cited by 2
Longitudinal Study of Transcriptomic Changes Occurring over Six Weeks of CHOP Treatment in Canine Lymphoma Identifies Prognostic Subtypes
Mee, M. W., Faulkner, S., Wood, G. A., Woods, J. P., Bienzle, D., & Coomber, B. L. (2024) · Veterinary Sciences · doi:10.3390/vetsci11110540 · Cited by 2
“The Ras/Raf/MEK/ERK signaling cascade is a key pathway involved in cell proliferation, differentiation, and survival [48,49].”
NCAPG-mediated CDK1 promotes malignant progression of non-small cell lung cancer via ERK signaling activation
Wu, Y. (2024) · American Journal of Cancer Research · doi:10.62347/dnaq7105 · Cited by 2
Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity
Andersen, M. D., Wolter, K., Enemark, M. B., Lauridsen, K. L., Hamilton-Dutoit, S. J., Starklint, J., d’Amore, F., Ludvigsen, M., Honoré, B., & Kamper, P. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2434170 · Cited by 2
“…that may be present in patients who subsequently develop BPT. Additional contributors to signal transduction include PIK3R4, which participates in the PI3K/AKT/ mTOR pathway, frequently implicated in cancer dysregulation, as well as MEK1 and MMP9, both involved in the MEK/ERK pathway [27–30].”
Amyotrophic Lateral Sclerosis and Parkinson's Disease: Brain Tissue Transcriptome Analysis Reveals Interactions
Fu, Z., Feng, B., Akogo, H. Y., Jiajia, M., Liu, Y., Quan, H., Zhang, X., Hou, Y., Zhang, X., Ma, J., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04681-9 · Cited by 2
ERK1/2 gene expression and hypomethylation of Alu and LINE1 elements in patients with type 2 diabetes with and without cataract: Impact of hyperglycemia‐induced oxidative stress
Nia, E. Z., Sadeghi, R. N., Ebadi, M., & Faghihi, M. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.14405 · Cited by 2
“It was shown that the MAPK signaling pathway plays an essential role in the development and progression of some diseases such as cataracts 5 , neurodegenerative diseases 6 , some types of cancers 7 , and also diabetes 8 and its complications such as diabetic nephropathy 9 , cardiomyopathy 10 .”
Effects of reduced extracellular sodium on proliferation and invasive activity of renal cell carcinoma cell lines
Naldi, L., Catalano, M., Melica, M. E., Polvani, S., Papini, D., Landini, I., Peri, A., & Roviello, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-92674-6 · Cited by 2
“Similarly, overexpression of the active form of the mitogen-activated protein kinase ERK has also been correlated with increased tumor progression through the activation of processes such as proliferation, survival, invasion and migration 27 .”
Bioinformatics analysis combined with experimental validation reveals the novel mechanisms of multi-targets of dapagliflozin attenuating diabetic liver injury
Wang, P., Sun, Z., Lan, Q., Zhang, Y., Song, Y., Yang, L., Chen, M., Shen, J., Huang, Q., & Zhang, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1519153 · Cited by 2
“Within, it played a crucial role in various biological processes, including maintaining cell morphology, differentiation, and proliferation (13, 14).”
ELMOD2 Overexpression Predicts Adverse Outcomes and Regulates Tumor Progression in Gliomas
Li, R., Liu, C., Wang, G.-J., Wang, Z., Li, R.-L., Lu, H.-T., Xie, X.-X., Zhang, Q., Feng, D., Yun, X., et al. (2025) · Current Medical Science · doi:10.1007/s11596-025-00057-9 · Cited by 2
“Studies have shown that ERK1/2 activation can phosphorylate multiple substrates that participate in key processes, such as cell proliferation, differentiation, migration, invasion, apoptosis, and cancerous transformation [25, 26].”
Achillea fragrantissima (Forssk.) Sch. Bip. essential oil inhibits the growth of pancreatic cancer cells via induction of necrosis, sub-G1 arrest, modulation of β-catenin/ERK signalling pathways and p38α MAPK, CDK2, EGFR inhibition
Break, M. K. B., Hussein, W., Alafnan, D., Almutairi, H. O., Katamesh, A. A., & Alshammari, M. D. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120201 · Cited by 2
RLIG1 promotes triple-negative breast cancer proliferation by activating mTORC1 signal pathway by interacting with ERK
Wang, Q., Chen, F., Pei, B., Jiang, G., Yang, Q., Xu, L., Gao, Y., Su, J., Huang, G., Zhou, F., et al. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111969 · Cited by 2
Mechanistic insights into the effect of midazolam on the malignant progression of ovarian cancer
Sun, X., Yu, H., Fu, B., & Zhang, Y. (2025) · CytoJournal · doi:10.25259/cytojournal_25_2025 · Cited by 2
“[27] Anesthetics affect the progression of ovarian cancer cells through the MAPK pathway.”
MAPK Cascade Signaling Is Involved in α-MMC Induced Growth Inhibition of Multiple Myeloma MM.1S Cells via G2 Arrest and Mitochondrial-Pathway-Dependent Apoptosis In Vitro
Cai, Z., Ye, T., Jiang, P.-W., Liao, Y., Wang, L., Zhang, Q.-L., Du, W.-Q., Huang, M., Yang, P. C., & Li, M. (2023) · Pharmaceuticals · doi:10.3390/ph16010124 · Cited by 2
“The MAPK/ERK pathway is involved in cell proliferation and differentiation, and its overactivation plays an important role in the occurrence and development of tumors [35].”
Background
Advances in the extracellular signal‐regulated kinase signaling pathway in silkworms, Bombyx mori (Lepidoptera)
Lv, J., Zheng, K., Wang, X., & Li, M. (2023) · Archives of Insect Biochemistry and Physiology · doi:10.1002/arch.22054 · Cited by 2
Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?
Clerk, A., Amadi, S. U., Smith, S. J., & Sugden, P. H. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100006 · Cited by 2
“For the ERK1/2 cascade [10,11], the core cascade is initiated by RAF family kinases of which there are 3 isoforms (RAF1, BRAF and ARAF).”
Background
Silvestrol alleviates glioblastoma progression through ERK pathway modulation and MANBA and NRG-1 expression
Zhou, L., ZHANG, Q., TIAN, B., & Yang, F. J. (2024) · Biocell · doi:10.32604/biocell.2024.049878 · Cited by 2
“MEK is the sole speci ﬁ c activator of ERK, with numerous substrates identi ﬁ ed for the ERK pathway [33].”
Targeted Molecular Profiling of Non-small Cell Lung Cancer in India
Dhungel, A., Mudagal, M. P., Sharma, U., Sariwan, S., Sharma, D., Vada, S., Janadri, S., Haribabu, T. E., & Matada, G. S. P. (2024) · Journal of Advanced Immunopharmacology · doi:10.5812/jai-141895 · Cited by 1
Beyond the Veil: Free Energy Profiles and Partition Coefficients for Antimelanoma Drugs in Self-Assembled Nanomicelles via COSMOmic and Atomistic Molecular Dynamics Simulations
Mio, A., Marson, D., Cavalieri, G., Fermeglia, M., Laurini, E., & Pricl, S. (2024) · Journal of Chemical & Engineering Data · doi:10.1021/acs.jced.4c00076 · Cited by 1
FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury
Gao, D., Shi, Y., Wang, Z., & Liu, W. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00077 · Cited by 1
The prognostic significance and potential mechanism of PFDN4 in hepatocellular carcinoma
Ye, J., Wang, J., Liu, R., Chen, C., & Wang, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113761 · Cited by 1
Echinococcus granulosus sensu lato promotes osteoclast differentiation through DUSP4-MAPK signaling in osseous echinococcosis
Sun, H., Liu, Y., Huang, Y., Xiong, K., Zhang, Z., Wang, W., Dai, Y., Li, J., Li, Q., Wang, S., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1558603 · Cited by 2
“MAPKs are widely regarded as important therapeutic targets for inflammatory diseases, including osteoporosis (Ullah et al., 2022; Gao et al., 2023), but the involvement of DUSP4 in osteoclast MAPK regulation has not been previously reported.”
Unraveling cutaneous histiocytosis: insights into histology, pathogenesis, diagnosis, and treatment pitfalls
Scurtu, L. G., Scurtu, F., & Simionescu, O. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1585815 · Cited by 1
CHML regulates migration and invasion in hepatocellular carcinoma via transcriptional and metabolic reprogramming
Cao, H., Wang, S., Zhang, L., Xie, H., Liu, Y., Kong, R., Yin, J., Lu, L., Jiang, J., & Liu, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1575809 · Cited by 1
“The MAPK cascade has been well-established to promote cell migration and invasion (35, 36).”
Peptide CCAT1-70aa promotes hepatocellular carcinoma proliferation and invasion via the MAPK/ERK pathway
Wu, X., Liang, R., Liu, G., Fang, Q., Xu, Z., Li, W., Tan, C. P., & Pu, J. (2025) · Open Medicine · doi:10.1515/med-2025-1206 · Cited by 1
“Subsequently, MEK1/2 phosphorylates substrates such as ERK, thereby regulating proliferation, di ﬀ erentiation, and migration, among others [37].”
Copine family members: Their molecular mechanisms in tumor progression and therapy resistance and their value in tumor diagnosis and prognosis evaluation
Li, S., Li, S., Kong, D., Yao, Q., & Fu, W. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152560 · Cited by 1
Dual-specific phosphatase 5 (DUSP5), upregulated in lung adenocarcinoma, as a potential therapeutic target for lung cancer
Kawabe, N., Komeda, K., Muraki, N., Sunaga, N., Taguchi, A., Iwabe, A., Minna, J. D., Tanaka, I., Matsushima, M., Kawabe, T., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152595 · Cited by 1
Insights Into the Separate and Joint Effects of Cadmium and Cesium on the Risk of Circadian Syndrome and the Underlying Mechanism: An Integrated Epidemiological and Network Toxicological Study
Huo, Z., Liu, W., Sun, Q., Song, J., Wan, S., Shi, W., Yang, Y., Hong, L., Liu, Q., Zhang, Y., et al. (2025) · Biological Trace Element Research · doi:10.1007/s12011-025-04808-6 · Cited by 1
Asymmetric coevolution of the MEK–ERK binding interface
Persikov, A. V., Marmion, R. A., & Shvartsman, S. Y. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110708 · Cited by 1
“Dysregulation of MEK, either through mutations or aberrant upstream signaling, can result in inappropriate ERK activation, contributing to pathological conditions, such as cancer and developmental disorders (9, 10).”
SIK2 activates the autophagy‒apoptosis pathway through SP1 regulation to inhibit the progression of hepatocellular carcinoma
Fan, S., Zhang, Y., Ma, P., Hou, H., Niu, R., Wang, Z., Zhang, J., Xia, Y., & Pan, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1635953 · Cited by 1
“Its activation status is typically characterized by phosphorylated ERK (pERK) levels (Fang and Richardson, 2005; Moon and Ro, 2021; Ullah et al., 2022).”
Bioactive sesquiterpene lactones with cytotoxic activity from Youngia japonica
Gong, H., Lin, K., Zhang, L., Huang, Y., Hu, L., Liu, X., Ming, H., Wang, S., He, Q., Ye, X., et al. (2025) · Phytochemistry Letters · doi:10.1016/j.phytol.2025.104064 · Cited by 1
Galectin-7 as a biomarker for aggressiveness and poor prognosis in thymic epithelial tumors
Lv, Y., Gu, Z., Li, K., Mao, T., Zhang, X., Xu, N., Fang, W., & Sun, Q. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102612 · Cited by 1
“MAPK signaling is a well-established oncogenic pathway implicated in various cancers, promoting cell proliferation, survival, and metastatic potential[31,32].”
Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer
Solé-Blanch, C., España, S., de la Puente-Noël, A., Marín-Béjar, O., Manzano, J. L., & Martínez‐Cardús, A. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189503 · Cited by 1
SYT15B promotes tumor progression through interaction with IQGAP1 to activate the MAPK pathway in lung adenocarcinoma
Ren, Y., Li, T., Zhou, H., Cui, Y., Li, C., Shen, W., Sun, H., Mao, H., Zhang, Z., Wang, Z., et al. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112302 · Cited by 1
Multi-Level Profiling of MAPK-Associated Genes and MicroRNAs Uncovers Regulatory Networks in Breast Cancer Subtypes
Król-Jatręga, K., Mitka-Krysiak, E., Boroń, K., Ossowski, P., Zmarzły, N., Ordon, P., Kulej, W., Sirek, T., Sirek, A., Boroń, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411831 · Cited by 1
“These findings illuminate the potential for subtype-specific MAPK-miRNA crosstalk to influence tumor behavior, therapeutic responsiveness, and prognosis [42].”
MAPK signaling reprogramming via integrative TCM-Western medicine strategy: mechanistic interactions between bioactive herbal components and chemotherapy in ovarian cancer therapy — a comprehensive review
Wang, S., Liu, F.-Y., & Han, F. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01872-3 · Cited by 1
“The ERK signaling pathway regulates cell proliferation, while the p38 MAPK and JNK signaling pathways regulate cell proliferation, cell death and inflammation [5].”
Small-molecule drug discovery in malignant melanoma: current status and prospective developments
Miao, X., Liu, Y., Li, C., Wu, J., Li, Y., Li, Z., Li, J., Sun, Y., & Han, J. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03515-0 · Cited by 1
“To date, no oncogenic mutations have been identi ﬁ ed in ARAF, implying that it is not a primary driver of aberrant ERK pathway activation in cancer [25].”
FAM111B promotes prostate cancer progression by inhibiting apoptosis via ATF3 suppression and MAPK pathway activation: a novel biomarker and therapeutic target
Wang, Y., Wang, Z., Yin, Z., Song, T., He, Y., Li, M., Wang, Z., Li, Z., Wang, P., Hu, Z., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04111-3 · Cited by 1
“Compris-ing the RAS, RAF, MEK, and ERK gene families, it regulates metabolic reprogramming and programmed cell death [19].”
Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway
Wu, N., Wu, Y., Zhang, Q., Naeem, M., Jing, R., Yb, L., & Yi, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1739944 · Cited by 1
Cleavage‐Resistant CYLD Protects Against Autoimmune Hepatitis
Liu, H., Su, C., Liu, J., Xing, M., Wu, X., Wang, L., Zhao, X., Zhang, H., Xie, Y., Wang, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.202513015 · Cited by 1
Stimuli-Responsive Microneedle: A Novel Frontier in Melanoma Therapy
Parhi, R. (2025) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00499-8 · Cited by 1
“As a result, MEK proteins become activated, leading to the development, replication, invasion, and metastasis of melanoma [59, 60].”
Tumor cell-intrinsic PD-1 in malignant ascites drives ovarian cancer progression via MAPK/ERK signaling
Xu, J., Shi, G., Qin, Z., Yin, B., Qiu, Y., Yu, Y., Zhang, H., He, J., Su, D., Zhang, Y., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03693-0 · Cited by 1
Systematic review of the efficacy and safety of lenvatinib vs. sorafenib as first-line treatments for hepatocellular carcinoma
Bo, W., Wang, Z., Dong, X., & Zou, J. (2026) · Clinics · doi:10.1016/j.clinsp.2026.100869 · Cited by 1
Ginsenoside compound K targets DUSP5 to inhibit the malignant progression of glioblastoma via the ERK pathway
Tang, F. N., Chen, H. N., Wang, S. N., Pang, J., He, S., Chen, X., Zhang, Y., Yang, J., & Zhang, Y. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178678 · Cited by 1
High-throughput screened kaempferitrin potentiates trastuzumab efficacy in HER2-positive gastric cancer by targeting Cyclooxygenase-2 to inhibit ERK signaling
Zhao, H., Yang, J., Yu, H., Liu, H., He, Q., Li, Z., Pan, F., Wu, L., Shi, W., & Jiao, Z. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158034 · Cited by 1
SCGB1A1 suppresses prostate cancer proliferation and metastasis by modulating the MAPK signaling pathway
Zhao, W., Zhou, X., Qi, G., Zhou, Y., & li, F. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05076-6 · Cited by 1
Exosomal Cargo-Derived Mediators of Ovarian Cancer Chemoresistance
Rutecki, S., Książek, K., & Mikuła‐Pietrasik, J. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-026-00844-7 · Cited by 1
“The activation of receptor tyrosine kinases (RTKs) and RAS genes initiates the events that lead to the activation of the MAPK pathway [36].”
A bioactive heart-derived ECM hydrogel potentiates Astragaloside IV–mediated microvascular regeneration
Lan, Y., Xu, Z., Li, Y., Liu, D., Lu, W., Li, Z., Chen, P., & Chen, G. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1800990 · Cited by 1
Targeting caveolin-1: dual challenges in tumor immunity and drug therapy strategies
Ge, X., Song, T., Guo, X., Li, J., Wang, Z., Shi, Y., Li, Q., & Zhang, C. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04324-0 · Cited by 1
“Thus, caveolae and Cav-1 play important roles in tumor development [25].”
Integrative analysis of tumor-educated platelets for stage-specific diagnosis, prognosis, and therapy in ovarian cancer
Gahin, S. G., Ibrahim, M. S., & Badr, E. (2026) · Discover Oncology · doi:10.1007/s12672-026-05011-2 · Cited by 1
“Finally, the “signaling via the receptor tyrosine kinase (RTK)” pathway was upregulated, consistent with the well-established role of RTK hyperactivation as a major driver of a variety of cancers [148], including OC [149].”
Tumor cell-derived IL-23 promotes hepatocellular carcinoma progression via an autocrine IL-23/EGFR/AKT signaling axis
Zhou, X., Chen, Y., Li, J., Zhang, Y., Li, J., & Guo, Y. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153893 · Cited by 1
The role of ERK signaling pathway in pituitary adenomas: from molecular mechanisms to targeted therapy
Ye, J., Wen, Y., Zhan, J., Hla, K. W. Y., Li, T., Xiao, Z., & Shu, X. (2026) · Growth Factors · doi:10.1080/08977194.2026.2671736 · Cited by 1
“The ERK/MAPK signaling pathway is central to regulating cell growth, development, and division, mainly through phosphorylation of various substrates to regulate cellular processes such as proliferation, differentiation, survival, and apoptosis (Guo et al. 2020; Ullah et al. 2022).”
Neuroinflammation in Epilepsy: Biochemical and Molecular Mechanisms and Implications for Natural Product-Driven Drug Discovery
Dias, A. L., da Silva, P. R., Souza, L. R. P., Pires, H. F. O., Gonçalves, M. C. F., Neri, L. C. D., Barbosa, N. M. M. V., Matos, A. L. L. D. S., Nayarisseri, A., Scotti, M. T., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135857 · Cited by 1
“In general, activation of these pathways occurs through a sequential phosphorylation cascade involving three levels of kinases: MAP kinase kinase kinases (MAP3Ks), MAP kinase kinases (MAP2Ks), and, finally, MAPKs [68].”
Proteomic characterization of SMARCA-deficient esophageal adenocarcinoma reveals complement evasion and DNA repair-associated prognostic subgroups
Grothey, B., Krämer, M., Montalbano, M., Lyu, S. I., Bruns, C. J., Zander, T., Büttner, R., & Quaas, A. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03534-7 · Cited by 1
“These results establish a foundation for several future research directions: functional validation of our proteomic ﬁ ndings, prospective clinical validation of identi ﬁ ed biomarkers, and development of targeted therapeutic strategies in SMARCA-de ﬁ cient tumours.”
Membrane bionic supramolecular nanomaterials for co-delivered of ribociclib and PEG10 siRNA for targeted therapy in breast cancer
Yu, Y., Liu, L., Cai, Y., Wang, T., Qiu, K., Huang, X., Wang, Y., Shi, M., Ni, M., Han, C., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218737 · Cited by 1
Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies
Li, H., Zhou, J., & Zhu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14081735 · Cited by 1
“The RAS/RAF/MEK/ERK signaling pathway, a core driver of tumor initiation and progression, plays a central role in tumorigenesis, malignant transformation, and metastasis by regulating cell cycle progression, apoptosis resistance, and invadopo-dia formation [30–32].”
6PPDQ Exposure Induces Mammary Developmental Damage through Mitochondrial Dysfunction Mediated by the p38 MAPK Signaling Pathway
Wang, C., Song, Y., Ma, M., Fu, Z., Zhang, N., & Jin, Y. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6c06357 · Cited by 1
Overexpression of LINC00853 enhances tumorigenesis and metastasis of gastric cancer
Xu, P., Gao, G., Yang, C., Wang, D., Chen, Y., Yao, S., Huang, Z., & Bian, Z. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.155065 · Cited by 1
Recent advancement of hybrid nanoparticles synthesis and applications in lung cancer management
Gouri, A., Sharma, A., Boddu, M., Mahendran, J., Mohanbhai, S. J., Sardoiwala, M. N., Choudhury, S. R., & Karmakar, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95303-0.00010-1 · Cited by 1
Lumican promotes gastric cancer progression by regulating the ERK pathway
Liu, G., Li, X., & Shen, X. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/32/20240872 · Cited by 1
Designing a predictive Framework: Immune-Related Gene-Based nomogram and prognostic model for kidney renal papillary cell carcinoma
Lim, A., Edderkaoui, M., Zhang, Y., Wang, Q., Wang, R., Pandol, S. J., & Ou, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111878 · Cited by 1
Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma
Yuan, Q., Shi, Y., Zhang, Y., Shi, Y., Hussain, Z., Zhao, J., Jiang, Y., Qiao, Y., Guo, Y., Lü, J., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03291-8 · Cited by 1
“MEK/ERK pathway has been identified as the most critical component of MAPK cascade [19].”
Background
IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression via ERK1/2 activation
Zhou, J., Chen, J.-R., Li, J., Han, S.-Q., Deng, X.-Y., Li, Z., Tong, W., Wang, C., Bai, Y., & Zhang, Y. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i3.102083 · Cited by 1
Clinical Significance of Copper Chaperone for Superoxide Dismutase in Colorectal Cancer
Takiguchi, N., Uemura, M., Osaki, M., Kusunoki, C., Paku, M., Takeda, M., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., et al. (2025) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.70109 · Cited by 1
Developing CuS for Predicting Aggressiveness and Prognosis in Lung Adenocarcinoma
Liu, H., Che, H., Zhang, M., Lv, J., Pu, C., Wu, J., Zhang, Y., & Gu, Y. (2023) · Genes · doi:10.3390/genes14051055 · Cited by 1
Dihydroartemisinin Enhances the Effects of Oxaliplatin by Activating PDCD5/ARAF mediated Signal Transduction in Colon CancerPreprint
Peng, Y., Zheng, Y., Qiu, J., Liu, J., Zou, J., Liu, C., & Chai, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-3353635/v1 · Cited by 1
KinAce: a web portal for exploring kinase-substrate interactionsPreprint
Sekar, J. A. P., Li, Y. C., Schlessinger, A., & Pandey, G. S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.08.570875 · Cited by 1
Heterobifunctional Compounds as BRAF Degraders for Treating Cancer
Sabnis, R. W. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00039
Loss of INI1 inhibits the expression of SIDT1 and promotes tumor progression in skull base chordoma by regulating EZH2-mediated H3K27me3Preprint
Zhang, Y., Shen, Y., Li, M., Xiong, Y., Ma, T., Bai, J., & Li, C. (2022) · Research Square · doi:10.21203/rs.3.rs-1995178/v1
Lumican promotes proliferation, migration and invasion of gastric cancer through ERK pathwayPreprint
Liu, G., Li, X., & Shen, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2679516/v1
YY1 promotes breast cancer metastasis via the DUSP6/p-ERK1/2 signaling axis 1Preprint
He, S., Zhou, Y. F., Xu, J., Zhang, Z., Zhang, J., Liu, Z., & Zhou, X. (2023) · Research Square · doi:10.21203/rs.3.rs-3292731/v1
Lactate Accelerates Cancer Progression Through the ERK-GCN5 Lactylation-Phosphorylation Feedback CascadePreprint
Huang, B., Chen, Y., Cui, G., Mer, G., Zhong, C., & Yuan, J. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4603952
Unveiling a BRAF Signature Proficient in Accurately Capturing Oncogenic Activity and Guiding Prognostic Prediction Across Multiple CancersPreprint
Yang, K., Yuan, Y., Fu, S., Liang, J., Li, F., & Bian, X. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4609997
Identification of SIRT4 as a novel paralog-specific interactor and candidate suppressor of C-RAF kinase in MAPK signalingPreprint
Mehrabipour, M., Dvorský, R., Nakhaei‐Rad, S., Lang, A., Verhülsdonk, P., Ahmadian, M. R., & Piekorz, R. P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.23.568463
“As a key component of the MAPK pathway, C-RAF is activated by upstream receptor-RAS signaling and subsequently activates various downstream effectors, particularly MEK1/2 kinases and thus ERK1/2 signaling (21,22,57).”
Background
Anticancer Effects of Fibronectin Leucine Rich Transmembrane Protein 3 as a Novel Therapeutic Molecule in Lung Cancer and Lung Cancer-derived Stem Cell
Baek, J.-W., & Kim, P. (2023) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2023.29.4.336
USP32 facilitates non-small cell lung cancer progression via deubiquitinating BAG3 and activating RAF-MEK-ERK signaling pathwayPreprint
李, 双., Yang, L., Ding, X., Sun, H., Dong, X., Yang, F., Wang, M., Zhang, H., Li, Y., Li, B., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3914278/v1
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Etxebeste, A. (2023) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.15581/10171/69185
RICH1 is a novel key suppressor of isoproterenol‑ or angiotensin II‑induced cardiomyocyte hypertrophy
Wang, S., Wang, X., Ling, L., Li, C., & Ren, Z. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13193
“…cleavage of rac1‑GTP to rac1‑GdP, which then inhibits the MaPK signaling pathway, which in turn reduces cellular proliferation and tumorigenesis (27,28). it has been reported that the overexpression of ricH1 inhibits the invasion and metastasis of breast cancer through down‑ regulating Hippo…”
Over-expression of KRT8 is associated with invasion of non-functioning pituitary adenomasPreprint
Chen, Y., Li, Q., Song, X., Jiang, Y., Liu, B., Li, Z., & Liu, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-4197540/v1
NCAPG mediated CDK1 promotes malignant progression of Non- small cell lung cancer by activating ERK signalingPreprint
Wu, Y., Yang, M., Chen, M., Tian, L., Zhu, Y., & Chen, L. (2024) · Research Square · doi:10.21203/rs.3.rs-4479922/v1
Determination of the effects of irisin hormone in SKMEL-30 cells
Türker, N. P., & Bakar, E. (2024) · Genetika · doi:10.2298/gensr2401089t
IL1RL2 is related to the expression and prognosis of bladder cancer
Ha, X., Li, Y., Gao, Z., Cui, J., Nie, Y., Sun, L., & Gao, W. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2773
Identificación de biomarcadores de resistencia a taxanos en cáncer de cabeza y cuello. Estudio de alternativas terapéuticas
Gestoso-Uzal, N. (2024) · Gredos (University of Salamanca) · doi:10.14201/gredos.159292
The noncanonical RNA-binding protein RAN stabilizes the mRNA of intranuclear stress granule assembly factor G3BP1 in nasopharyngeal carcinoma
Yang, P.-Y., Yang, Z., Lv, J., Jiang, P.-Y., Quan, T.-Q., Huang, Z.-H., Xu, X., Guo, R., Wei, D., & Sun, Y. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107964
Anti-arthritic effects of dibenzylbutane lignans from Litsea cubeba through suppression of MEK-ERK-p90RSK signallingPreprint
Dai, Y., Feng, K., Han, P., Wu, H., Shen, H., Zhang, Q., Jia, D., Qin, L., & Han, T. (2024) · Research Square · doi:10.21203/rs.3.rs-5346871/v1

Authors: Ullah, R., Yin, Q., Snell, A. H., & Wan, L.
Affiliations: Moffitt Cancer Center (US)
Corresponding author: Wan, Lixin
ORCID: Yin, Qing
Snell, Aidan H.
Wan, Lixin
Venue: Seminars in Cancer Biology
Publisher: Elsevier BV
Published: 2022-10
Volume: 85
Pages: 123-154
ISSN: 1044-579X (ISSN-L)
DOI: 10.1016/j.semcancer.2021.05.010
OpenAlex: W3160873367
Cited by: 553
References: 506
Citations by year: 2026: 123 · 2025: 164 · 2024: 173 · 2023: 69 · 2022: 19
FWCI: 7.08
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Seminars in Cancer Biology (publishedVersion)
PubMed (publishedVersion)
Funders: Melanoma Research Alliance
Florida Department of Health
American Cancer Society
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: Raf/MEK/ERK pathway, MAPK signaling, BRAF V600E mutation, Raf isoforms, MEK1/2, ERK1/2, Ras activation, receptor tyrosine kinase signaling, tumor evolution, cancer therapy, small molecule inhibitors, signaling crosstalk, oncogenic mutations
MeSH terms: Humans, Neoplasms, Signal Transduction, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RAF-MEK-ERK pathway in cancer evolution and treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks